Skye Bioscience, Inc. (SKYE)
1.765
0.00 (0.00%)
USD |
NASDAQ |
Sep 21, 16:00
1.84
+0.08
(+4.25%)
After-Hours: 20:00
Skye Bioscience Enterprise Value : -2.132M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | -2.132M |
| September 17, 2026 | -2.988M |
| September 16, 2026 | -2.417M |
| September 15, 2026 | -0.6162M |
| September 14, 2026 | -1.143M |
| September 11, 2026 | -0.9237M |
| September 10, 2026 | -0.748M |
| September 09, 2026 | -0.089M |
| September 08, 2026 | -1.627M |
| September 04, 2026 | -1.714M |
| September 03, 2026 | -2.066M |
| September 02, 2026 | -1.802M |
| September 01, 2026 | -1.978M |
| August 31, 2026 | -2.505M |
| August 28, 2026 | -2.088M |
| August 27, 2026 | -1.319M |
| August 26, 2026 | -1.012M |
| August 25, 2026 | -1.034M |
| August 24, 2026 | -0.3526M |
| August 21, 2026 | -0.0451M |
| August 20, 2026 | -0.031M |
| August 19, 2026 | 0.8651M |
| August 18, 2026 | 2.731M |
| August 17, 2026 | 4.703M |
| August 14, 2026 | 7.739M |
| Date | Value |
|---|---|
| August 13, 2026 | 9.128M |
| August 12, 2026 | 9.405M |
| August 11, 2026 | 9.124M |
| August 10, 2026 | 8.829M |
| August 07, 2026 | 8.368M |
| August 06, 2026 | 6.692M |
| August 05, 2026 | 9.855M |
| August 04, 2026 | 10.32M |
| August 03, 2026 | 10.65M |
| July 31, 2026 | 10.09M |
| July 30, 2026 | 10.51M |
| July 29, 2026 | 11.73M |
| July 28, 2026 | 11.72M |
| July 27, 2026 | 12.00M |
| July 24, 2026 | 13.02M |
| July 23, 2026 | 13.84M |
| July 22, 2026 | 12.61M |
| July 21, 2026 | 12.61M |
| July 20, 2026 | 13.09M |
| July 17, 2026 | 12.93M |
| July 16, 2026 | 12.21M |
| July 15, 2026 | 11.42M |
| July 14, 2026 | 11.91M |
| July 13, 2026 | 13.38M |
| July 10, 2026 | 14.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 75.86B |
| Viking Therapeutics, Inc. | 2.884B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.79M |
| Total Expenses (Quarterly) | 10.79M |
| EPS Diluted (Quarterly) | -2.174 |
| Earnings Yield | -576.8% |
| Normalized Earnings Yield | -550.82 |